APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza Vaccine

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Selected research

Market Analysis & Forecast

Global Influenza Vaccine Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchInfluenza Vaccine Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Influenza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Global Influenza Vaccine main players include CSL, GSK, Sanofi Pasteur, Mylan, Hulan Bio, AstraZeneca, CCBIO, etc., totally accounting for about 95% of market. North America is the largest market of Influenza Vaccine, with a share over 55%. As for the types of products, it can be divided into Trivalent Influenza Vaccine and Quadrivalent Influenza Vaccine. The most common product is Quadrivalent Influenza Vaccine, with a share over 95%. In terms of applications, it is widely used in For Children (6 months to 3 years) and For Adults and Children over 3 years. The most application is in Adults and Children over 3 years, with a share over 73%.

This report presents an overview of global market for Influenza Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

Read the full market overview

This report researches the key producers of Influenza Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Influenza Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenza Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Influenza Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Influenza Vaccine sales, projected growth trends, production technology, application and end-user industry.

Influenza Vaccine Segment by Company

CSL

GSK

Sanofi Pasteur

Mylan

Hulan Bio

AstraZeneca

CCBIO

Influenza Vaccine Segment by Type

Trivalent Influenza Vaccine

Quadrivalent Influenza Vaccine

Influenza Vaccine Segment by Application

For Children (6 months to 3 years)

For Adults and Children over 3 years

Influenza Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Influenza Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Influenza Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenza Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Influenza Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Trivalent Influenza Vaccine Major Manufacturers Table 3. Quadrivalent Influenza Vaccine Major Manufacturers Table 4. Global Influenza Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. For Children (6 months to 3 years) Major Manufacturers Table 6. For Adults and Children over 3 years Major Manufacturers Table 7. Influenza Vaccine Industry Trends Table 8. Influenza Vaccine Industry Drivers Table 9. Influenza Vaccine Industry Opportunities and Challenges Table 10. Influenza Vaccine Industry Restraints Table 11. Global Influenza Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Influenza Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Influenza Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Influenza Vaccine Revenue Market Share by Region (2021-2026) Table 15. Global Influenza Vaccine Revenue Market Share by Region (2027-2032) Table 16. Global Influenza Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (M Doses) Table 17. Global Influenza Vaccine Sales by Region (2021-2026) & (M Doses) Table 18. Global Influenza Vaccine Sales by Region (2027-2032) & (M Doses) Table 19. Global Influenza Vaccine Sales Market Share by Region (2021-2026) Table 20. Global Influenza Vaccine Sales Market Share by Region (2027-2032) Table 21. Global Influenza Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Influenza Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Influenza Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Influenza Vaccine Sales Market Share by Manufacturers (2021-2026) Table 25. Global Influenza Vaccine Sales Price (USD/Doses) of Manufacturers (2021-2026) Table 26. Global Influenza Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Influenza Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Influenza Vaccine Manufacturers, Product Type & Application Table 29. Global Influenza Vaccine Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Influenza Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Influenza Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Influenza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Influenza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Influenza Vaccine Revenue Market Share by Type (2021-2026) Table 36. Global Influenza Vaccine Revenue Market Share by Type (2027-2032) Table 37. Global Influenza Vaccine Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 38. Global Influenza Vaccine Sales by Type (2021-2026) & (M Doses) Table 39. Global Influenza Vaccine Sales by Type (2027-2032) & (M Doses) Table 40. Global Influenza Vaccine Sales Market Share by Type (2021-2026) Table 41. Global Influenza Vaccine Sales Market Share by Type (2027-2032) Table 42. Global Influenza Vaccine Price by Type (2021-2026) & (USD/Doses) Table 43. Global Influenza Vaccine Price by Type (2027-2032) & (USD/Doses) Table 44. Global Influenza Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Influenza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Influenza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Influenza Vaccine Revenue Market Share by Application (2021-2026) Table 48. Global Influenza Vaccine Revenue Market Share by Application (2027-2032) Table 49. Global Influenza Vaccine Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 50. Global Influenza Vaccine Sales by Application (2021-2026) & (M Doses) Table 51. Global Influenza Vaccine Sales by Application (2027-2032) & (M Doses) Table 52. Global Influenza Vaccine Sales Market Share by Application (2021-2026) Table 53. Global Influenza Vaccine Sales Market Share by Application (2027-2032) Table 54. Global Influenza Vaccine Price by Application (2021-2026) & (USD/Doses) Table 55. Global Influenza Vaccine Price by Application (2027-2032) & (USD/Doses) Table 56. CSL Company Information Table 57. CSL Business Overview Table 58. CSL Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 59. CSL Influenza Vaccine Product Portfolio Table 60. CSL Recent Development Table 61. GSK Company Information Table 62. GSK Business Overview Table 63. GSK Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 64. GSK Influenza Vaccine Product Portfolio Table 65. GSK Recent Development Table 66. Sanofi Pasteur Company Information Table 67. Sanofi Pasteur Business Overview Table 68. Sanofi Pasteur Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 69. Sanofi Pasteur Influenza Vaccine Product Portfolio Table 70. Sanofi Pasteur Recent Development Table 71. Mylan Company Information Table 72. Mylan Business Overview Table 73. Mylan Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 74. Mylan Influenza Vaccine Product Portfolio Table 75. Mylan Recent Development Table 76. Hulan Bio Company Information Table 77. Hulan Bio Business Overview Table 78. Hulan Bio Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 79. Hulan Bio Influenza Vaccine Product Portfolio Table 80. Hulan Bio Recent Development Table 81. AstraZeneca Company Information Table 82. AstraZeneca Business Overview Table 83. AstraZeneca Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 84. AstraZeneca Influenza Vaccine Product Portfolio Table 85. AstraZeneca Recent Development Table 86. CCBIO Company Information Table 87. CCBIO Business Overview Table 88. CCBIO Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 89. CCBIO Influenza Vaccine Product Portfolio Table 90. CCBIO Recent Development Table 91. North America Influenza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 92. North America Influenza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 93. North America Influenza Vaccine Sales by Type (2021-2026) & (M Doses) Table 94. North America Influenza Vaccine Sales by Type (2027-2032) & (M Doses) Table 95. North America Influenza Vaccine Sales Price by Type (2021-2026) & (USD/Doses) Table 96. North America Influenza Vaccine Sales Price by Type (2027-2032) & (USD/Doses) Table 97. North America Influenza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Influenza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Influenza Vaccine Sales by Application (2021-2026) & (M Doses) Table 100. North America Influenza Vaccine Sales by Application (2027-2032) & (M Doses) Table 101. North America Influenza Vaccine Sales Price by Application (2021-2026) & (USD/Doses) Table 102. North America Influenza Vaccine Sales Price by Application (2027-2032) & (USD/Doses) Table 103. North America Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Influenza Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 105. North America Influenza Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 106. North America Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 107. North America Influenza Vaccine Sales by Country (2021-2026) & (M Doses) Table 108. North America Influenza Vaccine Sales by Country (2027-2032) & (M Doses) Table 109. North America Influenza Vaccine Sales Price by Country (2021-2026) & (USD/Doses) Table 110. North America Influenza Vaccine Sales Price by Country (2027-2032) & (USD/Doses) Table 111. United States Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 112. Canada Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 113. Mexico Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 114. Europe Influenza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe Influenza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe Influenza Vaccine Sales by Type (2021-2026) & (M Doses) Table 117. Europe Influenza Vaccine Sales by Type (2027-2032) & (M Doses) Table 118. Europe Influenza Vaccine Sales Price by Type (2021-2026) & (USD/Doses) Table 119. Europe Influenza Vaccine Sales Price by Type (2027-2032) & (USD/Doses) Table 120. Europe Influenza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 121. Europe Influenza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 122. Europe Influenza Vaccine Sales by Application (2021-2026) & (M Doses) Table 123. Europe Influenza Vaccine Sales by Application (2027-2032) & (M Doses) Table 124. Europe Influenza Vaccine Sales Price by Application (2021-2026) & (USD/Doses) Table 125. Europe Influenza Vaccine Sales Price by Application (2027-2032) & (USD/Doses) Table 126. Europe Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Influenza Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 128. Europe Influenza Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 129. Europe Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 130. Europe Influenza Vaccine Sales by Country (2021-2026) & (M Doses) Table 131. Europe Influenza Vaccine Sales by Country (2027-2032) & (M Doses) Table 132. Europe Influenza Vaccine Sales Price by Country (2021-2026) & (USD/Doses) Table 133. Europe Influenza Vaccine Sales Price by Country (2027-2032) & (USD/Doses) Table 134. Germany Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 135. France Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 136. U.K. Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 137. Italy Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 138. Russia Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 139. Spain Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 140. Netherlands Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 141. Switzerland Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 142. Sweden Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 143. Poland Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 144. China Influenza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 145. China Influenza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 146. China Influenza Vaccine Sales by Type (2021-2026) & (M Doses) Table 147. China Influenza Vaccine Sales by Type (2027-2032) & (M Doses) Table 148. China Influenza Vaccine Sales Price by Type (2021-2026) & (USD/Doses) Table 149. China Influenza Vaccine Sales Price by Type (2027-2032) & (USD/Doses) Table 150. China Influenza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 151. China Influenza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 152. China Influenza Vaccine Sales by Application (2021-2026) & (M Doses) Table 153. China Influenza Vaccine Sales by Application (2027-2032) & (M Doses) Table 154. China Influenza Vaccine Sales Price by Application (2021-2026) & (USD/Doses) Table 155. China Influenza Vaccine Sales Price by Application (2027-2032) & (USD/Doses) Table 156. Asia Influenza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Influenza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Influenza Vaccine Sales by Type (2021-2026) & (M Doses) Table 159. Asia Influenza Vaccine Sales by Type (2027-2032) & (M Doses) Table 160. Asia Influenza Vaccine Sales Price by Type (2021-2026) & (USD/Doses) Table 161. Asia Influenza Vaccine Sales Price by Type (2027-2032) & (USD/Doses) Table 162. Asia Influenza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 163. Asia Influenza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia Influenza Vaccine Sales by Application (2021-2026) & (M Doses) Table 165. Asia Influenza Vaccine Sales by Application (2027-2032) & (M Doses) Table 166. Asia Influenza Vaccine Sales Price by Application (2021-2026) & (USD/Doses) Table 167. Asia Influenza Vaccine Sales Price by Application (2027-2032) & (USD/Doses) Table 168. Asia Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Asia Influenza Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. Asia Influenza Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. Asia Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 172. Asia Influenza Vaccine Sales by Country (2021-2026) & (M Doses) Table 173. Asia Influenza Vaccine Sales by Country (2027-2032) & (M Doses) Table 174. Asia Influenza Vaccine Sales Price by Country (2021-2026) & (USD/Doses) Table 175. Asia Influenza Vaccine Sales Price by Country (2027-2032) & (USD/Doses) Table 176. Japan Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 177. South Korea Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 178. India Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 179. Australia Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 180. Taiwan Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 181. Southeast Asia Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 182. SAMEA Influenza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 183. SAMEA Influenza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 184. SAMEA Influenza Vaccine Sales by Type (2021-2026) & (M Doses) Table 185. SAMEA Influenza Vaccine Sales by Type (2027-2032) & (M Doses) Table 186. SAMEA Influenza Vaccine Sales Price by Type (2021-2026) & (USD/Doses) Table 187. SAMEA Influenza Vaccine Sales Price by Type (2027-2032) & (USD/Doses) Table 188. SAMEA Influenza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 189. SAMEA Influenza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 190. SAMEA Influenza Vaccine Sales by Application (2021-2026) & (M Doses) Table 191. SAMEA Influenza Vaccine Sales by Application (2027-2032) & (M Doses) Table 192. SAMEA Influenza Vaccine Sales Price by Application (2021-2026) & (USD/Doses) Table 193. SAMEA Influenza Vaccine Sales Price by Application (2027-2032) & (USD/Doses) Table 194. SAMEA Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. SAMEA Influenza Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. SAMEA Influenza Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. SAMEA Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 198. SAMEA Influenza Vaccine Sales by Country (2021-2026) & (M Doses) Table 199. SAMEA Influenza Vaccine Sales by Country (2027-2032) & (M Doses) Table 200. SAMEA Influenza Vaccine Sales Price by Country (2021-2026) & (USD/Doses) Table 201. SAMEA Influenza Vaccine Sales Price by Country (2027-2032) & (USD/Doses) Table 202. Brazil Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 203. Argentina Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 204. Chile Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 205. Colombia Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 206. Peru Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 207. Saudi Arabia Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 208. Israel Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 209. UAE Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 210. Turkey Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 211. Iran Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 212. Egypt Influenza Vaccine Revenue (2021-2032) & (US$ Million) Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. Influenza Vaccine Distributors List Table 216. Influenza Vaccine Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. Influenza Vaccine Image Figure 2. Global Influenza Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Trivalent Influenza Vaccine Image Figure 5. Quadrivalent Influenza Vaccine Image Figure 6. Global Influenza Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Influenza Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. For Children (6 months to 3 years) Image Figure 9. For Adults and Children over 3 years Image Figure 10. Global Influenza Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Influenza Vaccine Revenue (2021-2032) & (US$ Million) Figure 12. Global Influenza Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Influenza Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Influenza Vaccine Revenue Market Share by Region (2021-2032) Figure 15. Global Influenza Vaccine Sales (2021-2032) & (M Doses) Figure 16. Global Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 17. Global Influenza Vaccine Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Influenza Vaccine Sales YoY (2021-2032) & (M Doses) Figure 19. Europe Influenza Vaccine Sales YoY (2021-2032) & (M Doses) Figure 20. China Influenza Vaccine Sales YoY (2021-2032) & (M Doses) Figure 21. Asia (Excluding China) Influenza Vaccine Sales YoY (2021-2032) & (M Doses) Figure 22. South America, Middle East and Africa Influenza Vaccine Sales YoY (2021-2032) & (M Doses) Figure 23. Global Influenza Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Influenza Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Influenza Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Influenza Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Influenza Vaccine Revenue Market Share by Type (2021-2032) Figure 29. Global Influenza Vaccine Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 30. Global Influenza Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Influenza Vaccine Sales Market Share by Type (2021-2032) Figure 32. Global Influenza Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Influenza Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Influenza Vaccine Revenue Market Share by Application (2021-2032) Figure 35. Global Influenza Vaccine Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 36. Global Influenza Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Influenza Vaccine Sales Market Share by Application (2021-2032) Figure 38. North America Influenza Vaccine Revenue Share by Type (2021-2032) Figure 39. North America Influenza Vaccine Sales Share by Type (2021-2032) Figure 40. North America Influenza Vaccine Revenue Share by Application (2021-2032) Figure 41. North America Influenza Vaccine Sales Share by Application (2021-2032) Figure 42. North America Influenza Vaccine Revenue Share by Country (2021-2032) Figure 43. North America Influenza Vaccine Sales Share by Country (2021-2032) Figure 44. Europe Influenza Vaccine Revenue Share by Type (2021-2032) Figure 45. Europe Influenza Vaccine Sales Share by Type (2021-2032) Figure 46. Europe Influenza Vaccine Revenue Share by Application (2021-2032) Figure 47. Europe Influenza Vaccine Sales Share by Application (2021-2032) Figure 48. Europe Influenza Vaccine Revenue Share by Country (2021-2032) Figure 49. Europe Influenza Vaccine Sales Share by Country (2021-2032) Figure 50. China Influenza Vaccine Revenue Share by Type (2021-2032) Figure 51. China Influenza Vaccine Sales Share by Type (2021-2032) Figure 52. China Influenza Vaccine Revenue Share by Application (2021-2032) Figure 53. China Influenza Vaccine Sales Share by Application (2021-2032) Figure 54. Asia Influenza Vaccine Revenue Share by Type (2021-2032) Figure 55. Asia Influenza Vaccine Sales Share by Type (2021-2032) Figure 56. Asia Influenza Vaccine Revenue Share by Application (2021-2032) Figure 57. Asia Influenza Vaccine Sales Share by Application (2021-2032) Figure 58. Asia Influenza Vaccine Revenue Share by Country (2021-2032) Figure 59. Asia Influenza Vaccine Sales Share by Country (2021-2032) Figure 60. SAMEA Influenza Vaccine Revenue Share by Type (2021-2032) Figure 61. SAMEA Influenza Vaccine Sales Share by Type (2021-2032) Figure 62. SAMEA Influenza Vaccine Revenue Share by Application (2021-2032) Figure 63. SAMEA Influenza Vaccine Sales Share by Application (2021-2032) Figure 64. SAMEA Influenza Vaccine Revenue Share by Country (2021-2032) Figure 65. SAMEA Influenza Vaccine Sales Share by Country (2021-2032) Figure 66. Influenza Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Influenza Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Trivalent Influenza Vaccine
  • Quadrivalent Influenza Vaccine
Applications
  • For Children (6 months to 3 years)
  • For Adults and Children over 3 years
Companies covered
  • CSL
  • GSK
  • Sanofi Pasteur
  • Mylan
  • Hulan Bio
  • AstraZeneca
  • CCBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Influenza Vaccine Market by Type
  3. 1.2.1 Global Influenza Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Trivalent Influenza Vaccine
  5. 1.2.3 Quadrivalent Influenza Vaccine
  6. 1.3 Influenza Vaccine Market by Application
  7. 1.3.1 Global Influenza Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 For Children (6 months to 3 years)
  9. 1.3.3 For Adults and Children over 3 years
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Influenza Vaccine Market Dynamics
  1. 2.1 Influenza Vaccine Industry Trends
  2. 2.2 Influenza Vaccine Industry Drivers
  3. 2.3 Influenza Vaccine Industry Opportunities and Challenges
  4. 2.4 Influenza Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Influenza Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Influenza Vaccine Revenue by Region
  3. 3.2.1 Global Influenza Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Influenza Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Influenza Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Influenza Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Influenza Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Influenza Vaccine Sales by Region
  9. 3.4.1 Global Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Influenza Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Influenza Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Influenza Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Influenza Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Influenza Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Influenza Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Influenza Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Influenza Vaccine Sales by Manufacturers
  6. 4.2.1 Global Influenza Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Influenza Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Influenza Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Influenza Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Influenza Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Influenza Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Influenza Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Influenza Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Influenza Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Influenza Vaccine Tier 1, Tier 2, and Tier 3
5 Influenza Vaccine Market by Type
  1. 5.1 Global Influenza Vaccine Revenue by Type
  2. 5.1.1 Global Influenza Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Influenza Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Influenza Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Influenza Vaccine Sales by Type
  6. 5.2.1 Global Influenza Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenza Vaccine Sales by Type (2021-2032) & (M Doses)
  8. 5.2.3 Global Influenza Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Influenza Vaccine Price by Type
6 Influenza Vaccine Market by Application
  1. 6.1 Global Influenza Vaccine Revenue by Application
  2. 6.1.1 Global Influenza Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Influenza Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Influenza Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Influenza Vaccine Sales by Application
  6. 6.2.1 Global Influenza Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Influenza Vaccine Sales by Application (2021-2032) & (M Doses)
  8. 6.2.3 Global Influenza Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Influenza Vaccine Price by Application
7 Company Profiles
  1. 7.1 CSL
  2. 7.1.1 CSL Company Information
  3. 7.1.2 CSL Business Overview
  4. 7.1.3 CSL Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 CSL Influenza Vaccine Product Portfolio
  6. 7.1.5 CSL Recent Developments
  7. 7.2 GSK
  8. 7.2.1 GSK Company Information
  9. 7.2.2 GSK Business Overview
  10. 7.2.3 GSK Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GSK Influenza Vaccine Product Portfolio
  12. 7.2.5 GSK Recent Developments
  13. 7.3 Sanofi Pasteur
  14. 7.3.1 Sanofi Pasteur Company Information
  15. 7.3.2 Sanofi Pasteur Business Overview
  16. 7.3.3 Sanofi Pasteur Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Pasteur Influenza Vaccine Product Portfolio
  18. 7.3.5 Sanofi Pasteur Recent Developments
  19. 7.4 Mylan
  20. 7.4.1 Mylan Company Information
  21. 7.4.2 Mylan Business Overview
  22. 7.4.3 Mylan Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Mylan Influenza Vaccine Product Portfolio
  24. 7.4.5 Mylan Recent Developments
  25. 7.5 Hulan Bio
  26. 7.5.1 Hulan Bio Company Information
  27. 7.5.2 Hulan Bio Business Overview
  28. 7.5.3 Hulan Bio Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hulan Bio Influenza Vaccine Product Portfolio
  30. 7.5.5 Hulan Bio Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Influenza Vaccine Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 CCBIO
  38. 7.7.1 CCBIO Company Information
  39. 7.7.2 CCBIO Business Overview
  40. 7.7.3 CCBIO Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 CCBIO Influenza Vaccine Product Portfolio
  42. 7.7.5 CCBIO Recent Developments
8 North America
  1. 8.1 North America Influenza Vaccine Market Size by Type
  2. 8.1.1 North America Influenza Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Influenza Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Influenza Vaccine Price by Type (2021-2032)
  5. 8.2 North America Influenza Vaccine Market Size by Application
  6. 8.2.1 North America Influenza Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Influenza Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Influenza Vaccine Price by Application (2021-2032)
  9. 8.3 North America Influenza Vaccine Market Size by Country
  10. 8.3.1 North America Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Influenza Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Influenza Vaccine Market Size by Type
  2. 9.1.1 Europe Influenza Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Influenza Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Influenza Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Influenza Vaccine Market Size by Application
  6. 9.2.1 Europe Influenza Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Influenza Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Influenza Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Influenza Vaccine Market Size by Country
  10. 9.3.1 Europe Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Influenza Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Influenza Vaccine Market Size by Type
  2. 10.1.1 China Influenza Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Influenza Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Influenza Vaccine Price by Type (2021-2032)
  5. 10.2 China Influenza Vaccine Market Size by Application
  6. 10.2.1 China Influenza Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Influenza Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Influenza Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Influenza Vaccine Market Size by Type
  2. 11.1.1 Asia Influenza Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Influenza Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Influenza Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Influenza Vaccine Market Size by Application
  6. 11.2.1 Asia Influenza Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Influenza Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Influenza Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Influenza Vaccine Market Size by Country
  10. 11.3.1 Asia Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Influenza Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Influenza Vaccine Market Size by Type
  2. 12.1.1 SAMEA Influenza Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Influenza Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Influenza Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Influenza Vaccine Market Size by Application
  6. 12.2.1 SAMEA Influenza Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Influenza Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Influenza Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Influenza Vaccine Market Size by Country
  10. 12.3.1 SAMEA Influenza Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Influenza Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Influenza Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Influenza Vaccine Value Chain Analysis
  2. 13.1.1 Influenza Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Influenza Vaccine Production Mode & Process
  6. 13.2 Influenza Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Influenza Vaccine Distributors
  9. 13.2.3 Influenza Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst